Title: 2010 AHA Guidelines: procainamide is back!
题目：2010年美国心脏病协会指南：普鲁卡因胺又回来了！
Author作者: AmalMattu

The September 5 2006 issue of Circulation contained a guideline, based on collaboration between the American Heart Assn, the American College of Cardiology, and the European Society of Cardiology, indicating that procainamide was preferable to amiodarone for the treatment of stable monomorphic ventricular tachycardia.
2006年9月5日由美国心脏病协会（AHA），美国心脏病学院，欧洲心脏病学会共同在美国‘循环’杂志发表了一个指南，指出普鲁卡因胺在治疗稳定性同型室颤时优于胺碘酮。

The 2010 AHA Guidelines have now also listed procainamide as the preferred drug for stable monomorphic ventricular tachycardia, giving it a Class IIa ("probably helpful") rating vs. amiodarone which has a Class IIb ("possibly helpful") rating. 

2010年AHA也将普鲁卡因胺列为在治疗稳定性同型室颤时的优选药，定位于IIa类（很可能有帮助），而胺碘酮则被列为IIb类（也许有帮助）。
Procainamide is also the safest drug for use in tachydysrhythmias when an accessory pathway (e.g. Wolff-Parkinson-White syndrome) is present.
普鲁卡因胺也是在治疗由侧束枝造成的快速心率紊乱（如预激综合征）时最安全的药。
The caveat is that neither procainamide nor amiodarone should be used in the presence of a prolonged QTc.


要注意的是普鲁卡因胺和胺碘酮在有QTc延长时不要用。
Acute care physicians should (re-)familiarize themselves with the use of procainamide, and emergency departments should maintain quick access to this drug to stay up-to-date with current national and international guidelines.


急诊医师要重新熟悉普鲁卡因胺的使用，急诊科要根据最新的国家或国际上的指南以保证这个药的及时应用。
References参考文献

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death — Executive Summary (many many authors) Circulation 2006;114:1088-1132.


Neumar RW, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729-767.